- The market continues to overlook NuCana and its fascinating ProTide platform technology, which could spawn a manifold of drugs that may outclass the existing standard of care products.
- The share price continues to be under pressure and has allowed me to enter NCNA at an attractive risk-reward. If all goes well, NCNA could be another potential multi-bagger.
- I provide an update on the company’s pipeline of nucleoside analogs. In addition, I discuss several upcoming catalysts that could have a drastic impact on the share price.
- As a final point, I update investors on my plan for amassing a substantial position in NCNA ahead of Acelarin's Phase III readout.
For further details see:
NuCana: The Market Continues To Overlook Its ProTide Platform Technology